Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.

MALDI imaging mass spectrometry represents a new analytical tool to directly provide the spatial distribution and relative abundance of proteins in tissue. Twenty-five ovary carcinomas (stages III and IV) and 23 benign ovaries were directly analyzed using MALDI-TOF MS. The biomarker with the major prevalence (80%) has been fully identified using MALDI MS and nanoESI MS and MS/MS after separation by RP-HPLC and trypsin enzymatic digestion. This marker with an m/z of 9744 corresponds to 84 amino acid residues from the 11S proteasome activator complex, named PA28 or Reg-alpha. Validation of this marker has been performed using MALDI imaging, classical immunocytochemistry with an antibody raised against the C-terminal part of the protein, specific MALDI imaging, and Western blot analysis. The validation, using immunocytochemistry, confirmed the epithelial localization of this fragment with nucleus localization in benign epithelial cells and a cytoplasmic localization in carcinoma cells. This indicates that this antibody could be used to discriminate the borderline tumor cases. At this point, a multicentric study needs to be conducted in order to clearly establish the potential of this biomarker. Taken together these studies reflect that direct tissue analysis and specific MALDI imaging strategies facilitate biomarker hunting and validation which can be named pathological proteomics.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian Cancer , 2002 .

[2]  Y. Liu Serum Proteomic Pattern Analysis for Early Cancer Detection , 2005, Advances in Bioinformatics and Its Applications.

[3]  H. R. Bergen,et al.  Discovery of Ovarian Cancer Biomarkers in Serum Using NanoLC Electrospray Ionization TOF and FT-ICR Mass Spectrometry , 2004, Disease markers.

[4]  Stanimire Tomov,et al.  Clinical Proteomics and Biomarker Discovery , 2004, Annals of the New York Academy of Sciences.

[5]  E. Petricoin,et al.  Biomarkers of ovarian tumours. , 2004, European journal of cancer.

[6]  P. Kloetzel,et al.  LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12 , 1996, The Journal of experimental medicine.

[7]  P. Collinet,et al.  Tumeurs de l'ovaire et CA 125 en 2006 , 2006 .

[8]  E. Kohn,et al.  Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature , 2004, Current opinion in oncology.

[9]  B. Seliger,et al.  Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin , 2000, Bone Marrow Transplantation.

[10]  E. Kohn,et al.  Proteomic analysis for early detection of ovarian cancer: A realistic approach? , 2003, International Journal of Gynecologic Cancer.

[11]  Ming Zhou,et al.  Cancer diagnosis using proteomic patterns , 2003, Expert review of molecular diagnostics.

[12]  Marie-Christine W. Gast,et al.  Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. , 2006, Trends in pharmacological sciences.

[13]  Timothy D. Veenstra,et al.  Proteomic patterns: their potential for disease diagnosis , 2005, Molecular and Cellular Endocrinology.

[14]  E. Petricoin,et al.  Clinical potential of proteomics in the diagnosis of ovarian cancer , 2002, Expert review of molecular diagnostics.

[15]  Hanno Langen,et al.  Biomarker Discovery by Imaging Mass Spectrometry , 2006, Molecular & Cellular Proteomics.

[16]  T. Regad,et al.  Role and fate of PML nuclear bodies in response to interferon and viral infections , 2001, Oncogene.

[17]  D. Vinatier,et al.  [Ovarian cancers and CA 125 in 2006]. , 2006, Gynecologie, obstetrique & fertilite.

[18]  B. Ye,et al.  New technologies for the identification of markers for early detection of ovarian cancer , 2003, Current opinion in obstetrics & gynecology.

[19]  H. Lai,et al.  Plasma proteomic pattern as biomarkers for ovarian cancer. , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[20]  I. Fournier,et al.  Tag-mass: specific molecular imaging of transcriptome and proteome by mass spectrometry based on photocleavable tag. , 2007, Journal of proteome research.

[21]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[22]  I. Fournier,et al.  Solid ionic matrixes for direct tissue analysis and MALDI imaging. , 2006, Analytical chemistry.

[23]  Xiao-Ying Meng,et al.  Classification of cancer types by measuring variants of host response proteins using SELDI serum assays , 2005, International journal of cancer.

[24]  G. Rice,et al.  Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer , 2004, British Journal of Cancer.

[25]  Douglas C Pearl,et al.  Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.

[26]  Kloetzel Pm The proteasome system: a neglected tool for improvement of novel therapeutic strategies? , 1998 .

[27]  Nuzhat Ahmed,et al.  Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer , 2005, Proteomics.

[28]  Mario Plebani,et al.  Proteomics: the next revolution in laboratory medicine? , 2005, Clinica chimica acta; international journal of clinical chemistry.

[29]  M. Fields,et al.  Ovarian cancer screening: a look at the evidence. , 2006, Clinical journal of oncology nursing.

[30]  Ying Liu,et al.  Serum Proteomic Pattern Analysis for Early Cancer Detection , 2005, Advances in Bioinformatics and Its Applications.

[31]  I. Fournier,et al.  MALDI-MS direct tissue analysis of proteins: Improving signal sensitivity using organic treatments. , 2006, Analytical chemistry.

[32]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[33]  Kathleen R. Cho,et al.  Classifications of ovarian cancer tissues by proteomic patterns , 2006, Proteomics.

[34]  P. Kloetzel,et al.  The effect of the interferon‐γ‐inducible processing machinery on the generation of a naturally tumor‐associated human cytotoxic T lymphocyte epitope within a wild‐type and mutant p53 sequence context , 2002, European journal of immunology.

[35]  E. Kohn,et al.  Promising directions for the diagnosis and management of gynecological cancers , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[36]  A. Rivett,et al.  Proteasome inhibitors: from in vitro uses to clinical trials , 2000, Journal of peptide science : an official publication of the European Peptide Society.

[37]  B. Rockhill Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.

[38]  T. Veenstra,et al.  The utility of proteomic patterns for the diagnosis of cancer. , 2004, Current drug targets. Immune, endocrine and metabolic disorders.

[39]  V. Fiano,et al.  Characterization of the 20S proteasome in human glioblastomas. , 2005, Anticancer research.

[40]  P. A. Peterson,et al.  In Vivo Assembly of the Proteasomal Complexes, Implications for Antigen Processing (*) , 1995, The Journal of Biological Chemistry.